

# **CLINIQUE BOUCHARD**

77, rue du Dr Escat  
13006 MARSEILLE  
France

Date: 22 / 12 / 2025

## **Patient: Ms Pamela Akhtar**

To whom it may concern,

We hereby confirm that the planned bariatric treatment for Ms Pamela Akhtar will be undertaken within the French state healthcare system (state healthcare sector), in accordance with applicable public healthcare regulations and tariffs.

### **Planned treatment dates**

- Phase 1 – Pre-operative assessment: 06/01/2026 (3 days)
- Phase 2 – Laparoscopic sleeve gastrectomy: 26/01/2026 (4 days)

### **Estimated costs**

- Phase 1: EUR 2,709.70
  - S2 eligible: EUR 2,625.70
  - Statutory co-payment: EUR 84.00
- Phase 2: EUR 4,889.65
  - S2 eligible: EUR 4,785.65
  - Statutory co-payment: EUR 104.00

Phase 2 costs are based on the standard public care pathway and may be adjusted a posteriori, in accordance with regulated public healthcare tariffs, depending on the patient's clinical profile, as detailed in the attached quotation.

### **S2 funding confirmation**

The total estimated cost is EUR 7,599.35, of which EUR 7,411.35 is eligible under the UK S2 scheme.

Clinique Bouchard formally confirms that it accepts a UK-issued S2 certificate as the form of payment for all eligible treatment costs.

No additional private charges will be billed beyond the statutory co-payments applicable under French public healthcare rules.

This confirmation is issued for the purpose of the UK S2 funding application.


Yours faithfully,

**Provider representative signing declaration:**

**Name:** Michael Fabre

**Job Title:** Directeur General / CEO

CLINIQUE BOUCHARD  
Mr Michael FABRE - Directeur  
77, rue du Dr Escat  
13006 MARSEILLE  
Email : michael.fabre@elsan.care  
Siret : 05781846000016



**Date of signature:** 22.12.2025